WO2004078163A3 - Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen - Google Patents

Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen Download PDF

Info

Publication number
WO2004078163A3
WO2004078163A3 PCT/US2004/006288 US2004006288W WO2004078163A3 WO 2004078163 A3 WO2004078163 A3 WO 2004078163A3 US 2004006288 W US2004006288 W US 2004006288W WO 2004078163 A3 WO2004078163 A3 WO 2004078163A3
Authority
WO
WIPO (PCT)
Prior art keywords
ester
api
acid
heterocyclic ring
amine
Prior art date
Application number
PCT/US2004/006288
Other languages
French (fr)
Other versions
WO2004078163A2 (en
Inventor
Oern Almarsson
Magali Bourghol Hickey
Matthew Peterson
Brian Moulton
Nair Rodriguez-Hornedo
Original Assignee
Transform Pharmaceuticals Inc
Univ South Florida
Univ Michigan
Oern Almarsson
Magali Bourghol Hickey
Matthew Peterson
Zaworotko Michael J
Brian Moulton
Nair Rodriguez-Hornedo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2003/006662 external-priority patent/WO2003074474A2/en
Priority claimed from US10/449,307 external-priority patent/US7078526B2/en
Priority claimed from PCT/US2003/019574 external-priority patent/WO2004000284A1/en
Priority claimed from PCT/US2003/027772 external-priority patent/WO2004078161A1/en
Priority claimed from US10/660,202 external-priority patent/US7927613B2/en
Priority claimed from PCT/US2003/041273 external-priority patent/WO2004061433A1/en
Application filed by Transform Pharmaceuticals Inc, Univ South Florida, Univ Michigan, Oern Almarsson, Magali Bourghol Hickey, Matthew Peterson, Zaworotko Michael J, Brian Moulton, Nair Rodriguez-Hornedo filed Critical Transform Pharmaceuticals Inc
Priority to JP2006508979A priority Critical patent/JP2007524596A/en
Priority to CA002514733A priority patent/CA2514733A1/en
Priority to EP04715190A priority patent/EP1631260A2/en
Priority to US10/546,963 priority patent/US20070059356A1/en
Priority to PCT/US2004/009947 priority patent/WO2004089313A2/en
Priority to US10/551,014 priority patent/US20060223794A1/en
Priority to US10/926,842 priority patent/US7446107B2/en
Priority to PCT/US2004/028456 priority patent/WO2005092884A1/en
Priority to EP04782868A priority patent/EP1718640A4/en
Priority to JP2007500742A priority patent/JP2007525502A/en
Priority to EP20040783308 priority patent/EP1670753A4/en
Priority to JP2006525508A priority patent/JP4842819B2/en
Publication of WO2004078163A2 publication Critical patent/WO2004078163A2/en
Publication of WO2004078163A3 publication Critical patent/WO2004078163A3/en
Priority to IL173575A priority patent/IL173575A0/en
Priority to NO20060669A priority patent/NO20060669L/en
Priority to US12/234,420 priority patent/US20090088443A1/en
Priority to IL199140A priority patent/IL199140A/en
Priority to US12/792,415 priority patent/US20100311701A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Abstract

A pharmaceutical composition comprising a co-crystal of an API and a co-crystal former; wherein the API has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphinic acid, phosphonic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, S-heterocyclic ring, thiophene, N-heterocyclic ring, pyrrole, 0-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, pyridine and the co-crystal former has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and methyl thio, such that the API and co-crystal former are capable of co-crystallizing from a solution phase under crystallization conditions.
PCT/US2004/006288 2002-02-15 2004-02-26 Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen WO2004078163A2 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
US10/546,963 US20070059356A1 (en) 2002-05-31 2004-02-26 Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
EP04715190A EP1631260A2 (en) 2003-02-28 2004-02-26 Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
CA002514733A CA2514733A1 (en) 2003-02-28 2004-02-26 Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
JP2006508979A JP2007524596A (en) 2003-02-28 2004-02-26 Co-crystal pharmaceutical composition
US10/551,014 US20060223794A1 (en) 2002-02-15 2004-03-31 Novel olanzapine forms and related methods of treatment
PCT/US2004/009947 WO2004089313A2 (en) 2003-04-01 2004-03-31 Novel olanzapine forms and related methods of treatment
US10/926,842 US7446107B2 (en) 2002-02-15 2004-08-26 Crystalline forms of conazoles and methods of making and using the same
PCT/US2004/028456 WO2005092884A1 (en) 2004-02-26 2004-09-01 Novel crystalline forms of conazoles and methods of making and using the same
EP04782868A EP1718640A4 (en) 2004-02-26 2004-09-01 Novel crystalline forms of conazoles and methods of making and using the same
JP2007500742A JP2007525502A (en) 2004-02-26 2004-09-01 Novel crystalline forms of conazoles and methods for their production and use
JP2006525508A JP4842819B2 (en) 2003-09-04 2004-09-04 Modafinil composition
EP20040783308 EP1670753A4 (en) 2003-09-04 2004-09-04 Modafinil compositions
IL173575A IL173575A0 (en) 2003-09-04 2006-02-07 Modafinil compositions
NO20060669A NO20060669L (en) 2003-09-11 2006-02-10 Modafinilsammensetninger
US12/234,420 US20090088443A1 (en) 2002-02-15 2008-09-19 Novel crystalline forms of conazoles and methods of making and using the same
IL199140A IL199140A (en) 2003-09-04 2009-06-03 Modafinil compositions
US12/792,415 US20100311701A1 (en) 2002-02-15 2010-06-02 Pharmaceutical Co-Crystal Compositions

Applications Claiming Priority (26)

Application Number Priority Date Filing Date Title
US45121303P 2003-02-28 2003-02-28
US60/451,213 2003-02-28
PCT/US2003/006662 WO2003074474A2 (en) 2002-03-01 2003-03-03 Multiple-component solid phases containing at least one active pharmaceutical ingredient
USPCT/US03/06662 2003-03-03
US45602703P 2003-03-18 2003-03-18
US60/456,027 2003-03-18
US46396203P 2003-04-18 2003-04-18
US60/463,962 2003-04-18
US10/449,307 2003-05-30
US10/449,307 US7078526B2 (en) 2002-05-31 2003-05-30 CIS-itraconazole crystalline forms and related processes, pharmaceutical compositions and methods
US10/601,092 2003-06-20
PCT/US2003/019574 WO2004000284A1 (en) 2002-06-21 2003-06-20 Pharmaceutical compositions with improved dissolution
USPCT/US03/19574 2003-06-20
US10/601,092 US20050025791A1 (en) 2002-06-21 2003-06-20 Pharmaceutical compositions with improved dissolution
US48706403P 2003-07-11 2003-07-11
US60/487,064 2003-07-11
USPCT/US03/27772 2003-09-04
PCT/US2003/027772 WO2004078161A1 (en) 2003-02-28 2003-09-04 Pharmaceutical co-crystal compositions of drugs such as carbamazeptine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US10/660,202 US7927613B2 (en) 2002-02-15 2003-09-11 Pharmaceutical co-crystal compositions
US10/660,202 2003-09-11
US50820803P 2003-10-02 2003-10-02
US60/508,208 2003-10-02
USPCT/US03/41273 2003-12-24
PCT/US2003/041273 WO2004061433A1 (en) 2002-12-30 2003-12-24 Pharmaceutical compositions with improved dissolution
US54275204P 2004-02-06 2004-02-06
US60/542,752 2004-02-06

Related Parent Applications (6)

Application Number Title Priority Date Filing Date
PCT/US2003/006662 Continuation-In-Part WO2003074474A2 (en) 2002-02-15 2003-03-03 Multiple-component solid phases containing at least one active pharmaceutical ingredient
US10/449,307 Continuation-In-Part US7078526B2 (en) 2002-02-15 2003-05-30 CIS-itraconazole crystalline forms and related processes, pharmaceutical compositions and methods
US10/601,092 Continuation-In-Part US20050025791A1 (en) 2002-02-15 2003-06-20 Pharmaceutical compositions with improved dissolution
US10/637,829 Continuation-In-Part US20040053853A1 (en) 2002-02-15 2003-08-08 Topiramate salts and compositions comprising and methods of making and using the same
PCT/US2003/027772 Continuation-In-Part WO2004078161A1 (en) 2002-02-15 2003-09-04 Pharmaceutical co-crystal compositions of drugs such as carbamazeptine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US10/660,202 Continuation-In-Part US7927613B2 (en) 2002-02-15 2003-09-11 Pharmaceutical co-crystal compositions

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10/601,092 Continuation-In-Part US20050025791A1 (en) 2002-02-15 2003-06-20 Pharmaceutical compositions with improved dissolution
US10/926,842 Continuation-In-Part US7446107B2 (en) 2002-02-15 2004-08-26 Crystalline forms of conazoles and methods of making and using the same
US12/792,415 Continuation US20100311701A1 (en) 2002-02-15 2010-06-02 Pharmaceutical Co-Crystal Compositions

Publications (2)

Publication Number Publication Date
WO2004078163A2 WO2004078163A2 (en) 2004-09-16
WO2004078163A3 true WO2004078163A3 (en) 2005-01-20

Family

ID=56290526

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/006288 WO2004078163A2 (en) 2002-02-15 2004-02-26 Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen

Country Status (4)

Country Link
EP (1) EP1631260A2 (en)
JP (1) JP2007524596A (en)
CA (1) CA2514733A1 (en)
WO (1) WO2004078163A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8555875B2 (en) 2008-12-23 2013-10-15 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds

Families Citing this family (392)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10129714A1 (en) 2001-06-22 2003-01-02 Bayer Ag Topical application of thiazolylamides
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
EP1494998A2 (en) 2002-03-01 2005-01-12 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
AU2003243354A1 (en) * 2002-05-31 2003-12-19 Transform Pharmaceuticals, Inc. Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
JP4842819B2 (en) * 2003-09-04 2011-12-21 セフアロン・インコーポレーテツド Modafinil composition
US7507823B2 (en) 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
EP1765379A4 (en) * 2004-06-17 2009-05-27 Transform Pharmaceuticals Inc Pharmaceutical co-crystal compositions and related methods of use
DE102005014248A1 (en) * 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Pharmaceutical preparation of N- [5- (aminosulfonyl) -4-methyl-1,3-thiazol-2-yl] -N-methyl-2- [4- (2-pyridinyl) phenyl] acetamide
WO2006138421A2 (en) * 2005-06-15 2006-12-28 Elan Pharma International Limited Nanoparticulate azelnidipine formulations
US20070099237A1 (en) * 2005-10-31 2007-05-03 The Regents Of The University Of Michigan Reaction co-crystallization of molecular complexes or co-crystals
AR057882A1 (en) * 2005-11-09 2007-12-26 Novartis Ag DOUBLE ACTION COMPOUNDS OF ANGIOTENSIN RECEPTOR BLOCKERS AND NEUTRAL ENDOPEPTIDASE INHIBITORS
EP1962600B1 (en) * 2005-12-08 2013-05-01 New Form Pharmaceuticals Inc. Metronidazole cocrystals
WO2008027557A2 (en) 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
US20080132419A1 (en) * 2006-10-04 2008-06-05 Nair Rodriguez-Hornedo Dissolution and precipitation of cocrystals with ionizable components
CA2666159A1 (en) * 2006-10-10 2008-05-29 Janssen Pharmaceutica Nv Novel crystal of (s)-(+)-2-(2-chlorophenyl)-2-hydroxy-ethyl carbamate
CA2618240C (en) 2006-11-17 2015-01-20 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
TW200901889A (en) 2007-02-09 2009-01-16 Basf Se Crystalline complexes of agriculturally active organic compounds
WO2008108639A1 (en) * 2007-03-08 2008-09-12 Avantium Holding B.V. Co-crystalline forms of carbamazepine
WO2008153945A2 (en) * 2007-06-06 2008-12-18 University Of South Florida Nutraceutical co-crystal compositions
EP2244712B1 (en) * 2008-01-22 2015-08-05 Thar Pharmaceuticals Inc. In vivo studies of crystalline forms of meloxicam
US7935817B2 (en) 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
US8519002B2 (en) 2008-04-07 2013-08-27 Takeda Pharmaceuticals U.S.A., Inc. Colchicine solid complex; methods of making; and methods of use thereof
US8003700B2 (en) * 2008-04-07 2011-08-23 Mutual Pharamaceutical Company, Inc. Colchicine solid complex; methods of making; and methods of use thereof
WO2009140466A2 (en) * 2008-05-14 2009-11-19 Dr. Reddy's Laboratories Ltd. Linezolid co-crystals
EP2123626A1 (en) 2008-05-21 2009-11-25 Laboratorios del Dr. Esteve S.A. Co-crystals of duloxetine and co-crystal formers for the treatment of pain
WO2009152347A2 (en) * 2008-06-13 2009-12-17 Bionevia Pharmaceuticals Inc. Crystalline forms of zotepine hydrochloride
US8258155B2 (en) 2008-06-30 2012-09-04 Mutual Pharmaceutical Company, Inc. Quinine sulfate/bisulfate solid complex; methods of making; and methods of use thereof
US8697735B2 (en) 2008-07-25 2014-04-15 Bionevia Pharmaceuticals, Inc. Solid forms of epalrestat
GB0813709D0 (en) * 2008-07-26 2008-09-03 Univ Dundee Method and product
US20110275679A1 (en) * 2008-08-06 2011-11-10 Bionevia Pharmaceuticals, Inc. Flupirtine hydrochloride maleic acid cocrystal
ES2639019T3 (en) 2008-09-06 2017-10-25 Bionevia Pharmaceuticals Inc. New co-crystal of epalrestat hill
EP2177215A1 (en) * 2008-10-17 2010-04-21 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of tramadol and NSAIDs
EP2199274A1 (en) * 2008-12-16 2010-06-23 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of tramadol and paracetamol
WO2010085589A2 (en) 2009-01-22 2010-07-29 G&H Brands Llc Desensitizing drug product
KR20100091127A (en) * 2009-02-09 2010-08-18 주식회사 한독약품 Novel salts of adefovir dipivoxil and method for the preparation of the same
JP5558875B2 (en) * 2009-03-19 2014-07-23 日本曹達株式会社 Novel inclusion complex, epoxy resin composition and epoxy resin composition for semiconductor encapsulation
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
AU2010247414B2 (en) 2009-05-15 2013-08-01 Novartis Ag Aryl pyridine as aldosterone synthase inhibitors
MX2011012199A (en) 2009-05-15 2011-12-08 Novartis Ag Benzoxazolone derivatives as aldosterone symthase inhibitors.
WO2010134085A1 (en) * 2009-05-20 2010-11-25 Institute Of Life Sciences Pharmaceutical co-crystals of quercetin
JP5466759B2 (en) 2009-05-28 2014-04-09 ノバルティス アーゲー Substituted aminobutyric acid derivatives as neprilysin inhibitors
PT2435409E (en) 2009-05-28 2014-11-05 Novartis Ag Substituted aminopropionic derivatives as neprilysin inhibitors
AR077490A1 (en) 2009-07-21 2011-08-31 Novartis Ag TOPICAL PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF A HYPERPROLIFERATIVE SKIN CONDITION
AR077328A1 (en) 2009-07-24 2011-08-17 Novartis Ag DERIVATIVES OF OXAZINE AND ITS USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
PT2459176T (en) 2009-07-31 2017-12-11 Gruenenthal Gmbh Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
EP2281558A1 (en) * 2009-08-06 2011-02-09 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical compounds of O-Desmethyl-Tramadol and COX-inhibitors
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
BR112012003262A8 (en) 2009-08-12 2016-05-17 Novartis Ag Heterocyclic Hydrazone Compounds and Their Uses to Treat Cancer and Inflammation
EP2467383A1 (en) 2009-08-20 2012-06-27 Novartis AG Heterocyclic oxime compounds
US20120149661A1 (en) 2009-08-26 2012-06-14 Novartis Ag Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
WO2011026904A1 (en) 2009-09-04 2011-03-10 Novartis Ag Pyrazinylpyridines useful for the treatment of proliferative diseases
US20110130380A1 (en) 2009-09-04 2011-06-02 Barsanti Paul A Heteroaryl Kinase Inhibitors
BR112012008147A2 (en) 2009-09-04 2016-03-01 Novartis Ag heteroaryl compounds as kinase inhibitors
JP2013504543A (en) 2009-09-10 2013-02-07 ノバルティス アーゲー Ether derivatives of bicyclic heteroaryls
EP2475661B1 (en) 2009-09-10 2013-10-23 Novartis AG Sulfonamides as inhibitors of bcl-2 family proteins for the treatment of cancer
EP2325172A1 (en) * 2009-11-02 2011-05-25 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of celecoxib and L-proline
JP5466767B2 (en) 2009-11-04 2014-04-09 ノバルティス アーゲー Heterocyclic sulfonamide derivatives useful as MEK inhibitors
US8519134B2 (en) 2009-11-17 2013-08-27 Novartis Ag Aryl-pyridine derivatives as aldosterone synthase inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors
US8575160B2 (en) 2009-11-30 2013-11-05 Novartis Ag Imidazole derivatives as aldosterone synthase inhibitors
WO2011073316A1 (en) 2009-12-18 2011-06-23 Novartis Ag 4-aryl-butane-1,3-diamides
ES2459496T3 (en) 2009-12-21 2014-05-09 Novartis Ag Diaza-spiro [5.5] undecans as orexin receptor antagonists
WO2011076744A1 (en) 2009-12-21 2011-06-30 Novartis Ag Disubstituted heteroaryl-fused pyridines
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
SG181431A1 (en) 2009-12-31 2012-07-30 Novartis Ag Pyrazine derivatives and their use in the treatment of neurological disorders
AR080056A1 (en) 2010-02-01 2012-03-07 Novartis Ag CICLOHEXIL-AMIDA DERIVATIVES AS ANTAGONISTS OF CRF RECEIVERS
US20120295942A1 (en) 2010-02-01 2012-11-22 Nicholas James Devereux Pyrazolo[5,1b]oxazole Derivatives as CRF-1 Receptor Antagonists
CN102753527B (en) 2010-02-02 2014-12-24 诺华股份有限公司 Cyclohexyl amide derivatives as crf receptor antagonists
US8791100B2 (en) 2010-02-02 2014-07-29 Novartis Ag Aryl benzylamine compounds
US8415507B2 (en) 2010-02-03 2013-04-09 Laurus Labs Private Limited Pterostilbene cocrystals
UY33236A (en) 2010-02-25 2011-09-30 Novartis Ag DIMERIC INHIBITORS OF THE IAP
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
AR082453A1 (en) 2010-04-21 2012-12-12 Novartis Ag FUROPIRIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USES OF THE SAME
CN102933205B (en) * 2010-04-28 2014-08-13 诺弗米克斯有限公司 Cilostazol cocrystals and compositions
US20130053381A1 (en) 2010-05-20 2013-02-28 Novartis Ag 2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl-sulfonamide derivatives
WO2011157793A1 (en) 2010-06-17 2011-12-22 Novartis Ag Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
CN102947274A (en) 2010-06-17 2013-02-27 诺瓦提斯公司 Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
UY33469A (en) 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag COMPOSITIONS AND METHODS TO MODULATE THE WNT SIGNALING ROAD
UA112517C2 (en) 2010-07-06 2016-09-26 Новартіс Аг TETRAHYDROPYRIDOPYRIMIDINE DERIVATIVES
KR101391041B1 (en) 2010-07-13 2014-05-07 노파르티스 아게 oxazine derivatives and their use in the treatment of neurological disorders
PL2593452T3 (en) 2010-07-14 2017-07-31 Novartis Ag Ip receptor agonist heterocyclic compounds
BR112013001516A2 (en) 2010-07-22 2016-06-07 Novartis Ag 2,3,5-trisubstituted thiophene compounds and uses thereof
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
NZ608116A (en) 2010-09-13 2014-05-30 Novartis Ag Triazine-oxadiazoles
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
UY33616A (en) 2010-09-20 2012-04-30 Envivo Pharmaceuticals Inc COMPOUNDS WITH IMIDAZOTRIAZINONA STRUCTURE
WO2012048235A1 (en) 2010-10-08 2012-04-12 Novartis Ag Vitamin e formulations of sulfamide ns3 inhibitors
US20120101110A1 (en) 2010-10-26 2012-04-26 Sangamesh Badiger Diaza-spiro[5.5]undecanes
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8993631B2 (en) 2010-11-16 2015-03-31 Novartis Ag Method of treating contrast-induced nephropathy
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
UY33794A (en) 2010-12-13 2012-07-31 Novartis Ag DIMERIC INHIBITORS OF THE IAP
US20130266590A1 (en) 2010-12-13 2013-10-10 Novartis Ag Dimeric iap inhibitors
CU24152B1 (en) 2010-12-20 2016-02-29 Irm Llc 1,2 OXAZOL-8-AZABICICLO [3,2,1] OCTANO 8 IL AS FXR MODULATORS
US20140039007A1 (en) 2010-12-20 2014-02-06 David C. Tully Compositions and methods for modulating farnesoid x receptors
CN103370315A (en) 2010-12-20 2013-10-23 Irm责任有限公司 Compositions and methods for modulating farnesoid x receptors
WO2012084873A1 (en) 2010-12-20 2012-06-28 Novartis Ag 4- (hetero) aryl - ethynyl - octahydro - indole - 1 - carboxylic acid esters
US20120165331A1 (en) 2010-12-22 2012-06-28 Sangamesh Badiger Di/tri-aza-spiro-C9-C11alkanes
CN103402996B (en) 2011-01-04 2015-02-11 诺瓦提斯公司 Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (AMD)
KR20140051822A (en) 2011-01-12 2014-05-02 노파르티스 아게 Oxazine derivatives and their use in the treatment of neurological disorders
CA2824493A1 (en) 2011-01-13 2012-07-19 Novartis Ag Bace-2 inhibitors for the treatment of metabolic disorders
EP2663561B1 (en) 2011-01-13 2016-03-16 Novartis AG Novel heterocyclic derivatives and their use in the treatment of neurological disorders
WO2012098501A1 (en) * 2011-01-21 2012-07-26 Ranbaxy Laboratories Limited Febuxostat co-crystals
US9067881B2 (en) 2011-01-24 2015-06-30 Novartis Ag 4-tolyl-ethynyl-octahydro-indole-1-ester derivatives
WO2012101064A1 (en) 2011-01-28 2012-08-02 Novartis Ag N-acyl pyrimidine biaryl compounds as protein kinase inhibitors
WO2012101065A2 (en) 2011-01-28 2012-08-02 Novartis Ag Pyrimidine biaryl amine compounds and their uses
WO2012101063A1 (en) 2011-01-28 2012-08-02 Novartis Ag N-acyl pyridine biaryl compounds and their uses
WO2012101066A1 (en) 2011-01-28 2012-08-02 Novartis Ag Pyridine biaryl amine compounds and their uses
AU2012213080B2 (en) 2011-01-31 2014-03-27 Novartis Ag Novel heterocyclic derivatives
WO2012104823A2 (en) 2011-02-04 2012-08-09 Novartis Ag Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
AP2013007103A0 (en) 2011-02-25 2013-09-30 Irm Llc Compounds and compositions as TRK inhibitors
GB201103578D0 (en) 2011-03-02 2011-04-13 Sabrepharm Ltd Dipyridinium derivatives
US20130338152A1 (en) 2011-03-08 2013-12-19 Irm Llc Fluorophenyl bicyclic heteroaryl compounds
WO2012129568A2 (en) * 2011-03-24 2012-09-27 University Of South Florida Lithium compositions
US8748435B2 (en) 2011-04-01 2014-06-10 Novartis Ag Pyrazolo pyrimidine derivatives
WO2012138648A1 (en) 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
US8614195B2 (en) 2011-04-14 2013-12-24 Novartis Ag Glycoside derivatives and uses thereof
MX2013011926A (en) 2011-04-14 2013-11-01 Novartis Ag Glycoside derivatives and uses thereof.
EP2517700B1 (en) * 2011-04-28 2013-07-17 Zentiva, k.s. Pharmaceutically acceptable cocrystals of N-[2-(7-methoxy-1-naphthyl]acetamide and methods of their preparation
UY34072A (en) 2011-05-17 2013-01-03 Novartis Ag INDOL SUBSTITUTED DERIVATIVES
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
US8859586B2 (en) 2011-06-20 2014-10-14 Novartis Ag Cyclohexyl isoquinolinone compounds
EP2721008B1 (en) 2011-06-20 2015-04-29 Novartis AG Hydroxy substituted isoquinolinone derivatives as p53 (mdm2 or mdm4) inhibitors
PT2729142T (en) 2011-07-08 2018-10-01 Novartis Ag Method of treating atherosclerosis in high triglyceride subjects
JP6145451B2 (en) 2011-07-08 2017-06-14 ノバルティス アーゲー Novel pyrrolopyrimidine derivatives
US9056843B2 (en) 2011-07-08 2015-06-16 Novartis Ag Trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
JP2014521635A (en) 2011-07-27 2014-08-28 ノバルティス アーゲー Pyrazoline derivatives and their use as selective androgen receptor modulators
UY34278A (en) 2011-08-25 2013-04-05 Novartis Ag NEW NOXEDINE DERIVATIVES OF OXAZINE AND ITS USE IN THE TREATMENT OF DISEASES
AU2012302176A1 (en) 2011-09-01 2014-04-17 Irm Llc Compounds and compositions as c-kit kinase inhibitors
US9199981B2 (en) 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
KR20140105433A (en) 2011-09-01 2014-09-01 아이알엠 엘엘씨 Compounds and compositions as pdgfr kinase inhibitors
UY34305A (en) 2011-09-01 2013-04-30 Novartis Ag DERIVATIVES OF BICYCLIC HETEROCICLES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
EA201490539A1 (en) 2011-09-01 2014-06-30 АйАрЭм ЭлЭлСи COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS
WO2013033167A1 (en) 2011-09-01 2013-03-07 Irm Llc Compounds and compositions as c-kit kinase inhibitors
JO3192B1 (en) 2011-09-06 2018-03-08 Novartis Ag Benzothiazolone compound
JP5957526B2 (en) 2011-09-15 2016-07-27 ノバルティス アーゲー 6-Substituted 3- (quinolin-6-ylthio)-[1,2,4] triazolo [4,3-A] pyrazine as tyrosine kinase
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038386A1 (en) 2011-09-16 2013-03-21 Novartis Ag Heterocyclic compounds for the treatment of cystic fibrosis
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
JP6165733B2 (en) 2011-09-16 2017-07-19 ノバルティス アーゲー N-substituted heterocyclylcarboxamides
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
TW201321353A (en) 2011-10-08 2013-06-01 Novartis Ag Carbamate/urea derivatives
MX2014004479A (en) 2011-10-13 2014-08-01 Novartis Ag Novel oxazine derivatives and their use in the treatment of disease.
TWI580442B (en) * 2011-10-19 2017-05-01 傑特大學 Pharmaceutical nanosuspension
US20140249139A1 (en) 2011-10-21 2014-09-04 Novartis Ag Quinazoline Derivatives
KR20140090218A (en) 2011-10-28 2014-07-16 노파르티스 아게 Novel purine derivatives and their use in the treatment of disease
CN104159584A (en) 2011-11-25 2014-11-19 诺弗米克斯有限公司 Aprepitant L-proline solvates - compositions and cocrystals
MX2014006409A (en) 2011-11-28 2014-07-30 Novartis Ag Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease.
US8969341B2 (en) 2011-11-29 2015-03-03 Novartis Ag Pyrazolopyrrolidine compounds
WO2013093850A1 (en) 2011-12-22 2013-06-27 Novartis Ag Quinoline derivatives
LT2794600T (en) 2011-12-22 2018-02-26 Novartis Ag 2,3-dihydro-benzo[1,4]oxazine derivatives and related compounds as phosphoinositide-3 kinase (pi3k) inhibitors for the treatment of e.g. rheumatoid arthritis
EP2802582A1 (en) 2012-01-13 2014-11-19 Novartis AG Fused dihydropyrido [2,3 -b]pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
TW201335160A (en) 2012-01-13 2013-09-01 Novartis Ag IP receptor agonist heterocyclic compounds
EP2802581A1 (en) 2012-01-13 2014-11-19 Novartis AG 7,8- dihydropyrido [3, 4 - b]pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
WO2013105065A1 (en) 2012-01-13 2013-07-18 Novartis Ag Fused piperidines as ip receptor agonists for the treatment of pah and related disorders
US20150005311A1 (en) 2012-01-13 2015-01-01 Novartis Ag IP receptor agonist heterocyclic compounds
JO3357B1 (en) 2012-01-26 2019-03-13 Novartis Ag Imidazopyrrolidinone compounds
EP2807157A1 (en) 2012-01-27 2014-12-03 Novartis AG 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
WO2013111107A1 (en) 2012-01-27 2013-08-01 Novartis Ag Aminopyridine derivatives as plasma kallikrein inhibitors
UY34646A (en) 2012-03-02 2013-10-31 Novartis Ag ESPIROHIDANTOINE COMPOUNDS AND THEIR USE AS SELECTIVE MODULATORS OF THE ANDROGEN RECEIVER
WO2013142269A1 (en) 2012-03-19 2013-09-26 Envivo Pharmaceuticals, Inc. Imidazotriazinone compounds
EP2841432A1 (en) 2012-04-27 2015-03-04 Novartis AG Tetrahydropyran dgat1 inhibitors
ES2624291T3 (en) 2012-04-27 2017-07-13 Novartis Ag DGAT1 cyclic ether bond inhibitors
EA201491990A1 (en) 2012-05-03 2015-02-27 Новартис Аг L-MALATE SALT OF 2,7-DIAZASPIRO [4.5] DEC-7-silt derivatives and their crystalline forms as agonists of creeline receptors
AP2014008040A0 (en) 2012-05-04 2014-10-31 Novartis Ag Complement pathway modulators and uses thereof
US20130310387A1 (en) 2012-05-16 2013-11-21 Novartis Ag Monocyclic Heteroaryl Cycloalkyldiamine Derivatives
US9365576B2 (en) 2012-05-24 2016-06-14 Novartis Ag Pyrrolopyrrolidinone compounds
US20150152083A1 (en) 2012-06-06 2015-06-04 Irm Llc, A Delaware Limited Liability Company Compounds and Compositions for Modulating EGFR Activity
JO3300B1 (en) 2012-06-06 2018-09-16 Novartis Ag Compounds and compositions for modulating egfr activity
BR112014031292A2 (en) * 2012-06-15 2017-06-27 Basf Se multi-component crystalline system, process for obtaining crystalline composition, and pharmaceutical composition
ES2584702T3 (en) 2012-06-20 2016-09-28 Novartis Ag Complement path modulators and uses thereof
CA2877030A1 (en) * 2012-06-22 2013-12-27 Basf Se Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers
US20150191462A1 (en) 2012-06-28 2015-07-09 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
EP2867227B1 (en) 2012-06-28 2018-11-21 Novartis AG Complement pathway modulators and uses thereof
JP6154897B2 (en) 2012-06-28 2017-06-28 ノバルティス アーゲー Pyrrolidine derivatives and their use as complement pathway regulators
US9468661B2 (en) 2012-06-28 2016-10-18 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
US9388199B2 (en) 2012-06-28 2016-07-12 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
EP2867226B1 (en) 2012-06-28 2018-11-14 Novartis AG Complement pathway modulators and uses thereof
WO2014009833A2 (en) 2012-07-12 2014-01-16 Novartis Ag Complement pathway modulators and uses thereof
US9034874B2 (en) 2012-07-20 2015-05-19 Novartis Ag Carbamate/urea derivatives
KR101303803B1 (en) 2012-08-02 2013-09-04 순천향대학교 산학협력단 Preparation of co-crystals of various drug substances including cabamazepine-saccharin co-crystals by anti-solvent method
KR20150042256A (en) 2012-08-13 2015-04-20 노파르티스 아게 Bicyclic heteroaryl cycloalkyldiamine derivatives as inhibitors of spleen tyrosine kinases (syk)
MY174339A (en) 2012-08-13 2020-04-09 Novartis Ag 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions
EP2890687B1 (en) 2012-08-30 2017-06-28 Novartis AG Salts of benzothiazolone compound as beta-2-adrenoceptor agonist
WO2014033631A1 (en) 2012-08-31 2014-03-06 Novartis Ag N-(3-pyridyl) biarylamides as kinase inhibitors
WO2014033630A1 (en) 2012-08-31 2014-03-06 Novartis Ag Novel aminothiazole carboxamides as kinase inhibitors
ES2671478T3 (en) 2012-08-31 2018-06-06 Novartis Ag 2'-ethinyl nucleoside derivatives for the treatment of viral infections
EP2892880B1 (en) 2012-09-07 2017-11-22 Novartis AG Indole carboxamide derivatives and uses thereof
IN2015DN01328A (en) 2012-09-19 2015-07-03 Novartis Ag
US20150216867A1 (en) 2012-09-25 2015-08-06 Novartis Ag Compounds for use in gastric complication
WO2014052619A1 (en) 2012-09-27 2014-04-03 Irm Llc Piperidine derivatives and compositions as modulators of gpr119 activity
JP2015532277A (en) 2012-09-29 2015-11-09 ノバルティス アーゲー Cyclic peptides and their use as pharmaceuticals
US9394257B2 (en) 2012-10-16 2016-07-19 Tolero Pharmaceuticals, Inc. PKM2 modulators and methods for their use
EA201590886A1 (en) 2012-11-07 2015-08-31 Новартис Аг SUBSTITUTED INDOLA DERIVATIVES
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
DK2925757T3 (en) 2012-11-19 2018-01-15 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US20150291598A1 (en) 2012-11-19 2015-10-15 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
US9649314B2 (en) 2012-12-13 2017-05-16 Novartis Ag Pyrimido[4,5-b]quinoline-4,5(3H,10H)-diones
CA2895086A1 (en) 2012-12-13 2014-06-19 Novartis Ag Pyridone derivatives and uses thereof in the treatment of tuberculosis
MX2015007936A (en) 2012-12-19 2016-03-11 Novartis Ag Autotaxin inhibitors.
CN105008370B (en) 2012-12-19 2017-06-09 诺华股份有限公司 As the tricyclic compound of CFTR inhibitor
US20150336960A1 (en) 2012-12-19 2015-11-26 Novartis Ag Aryl-substituted fused bicyclic pyridazine compounds
WO2014097148A1 (en) 2012-12-19 2014-06-26 Novartis Ag Tricyclic compounds for inhibiting the cftr channel
US9403827B2 (en) 2013-01-22 2016-08-02 Novartis Ag Substituted purinone compounds
EP2948453B1 (en) 2013-01-22 2017-08-02 Novartis AG Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
US9040712B2 (en) 2013-01-23 2015-05-26 Novartis Ag Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions
WO2014125413A1 (en) 2013-02-13 2014-08-21 Novartis Ag Ip receptor agonist heterocyclic compounds
EA028583B1 (en) 2013-02-14 2017-12-29 Новартис Аг Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
WO2014128612A1 (en) 2013-02-20 2014-08-28 Novartis Ag Quinazolin-4-one derivatives
JP6230626B2 (en) 2013-02-28 2017-11-15 ノバルティス アーゲー Formulations containing benzothiazolone compounds
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
US9475806B2 (en) 2013-03-14 2016-10-25 Novartis Ag Complement factor B inhibitors and uses there of
UY35400A (en) 2013-03-15 2014-10-31 Novartis Ag COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITARY DISEASES
US9186361B2 (en) 2013-03-15 2015-11-17 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
WO2014160649A1 (en) 2013-03-29 2014-10-02 Novartis Ag Hydroxamic acid derivatives as lpxc inhibitors for the treatment of bacterial infections
WO2014167528A1 (en) 2013-04-11 2014-10-16 Novartis Ag Spiropyrazolopyridine derivatives and uses thereof for the treatment of viral infections
EP2991999B1 (en) 2013-04-29 2019-05-08 Mapi Pharma Limited Dapagliflozin lactose co-crystal
US20150018376A1 (en) 2013-05-17 2015-01-15 Novartis Ag Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
EP3412675A1 (en) 2013-05-27 2018-12-12 Novartis AG Imidazopyrrolidinone derivatives and their use in the treatment of disease
US8975417B2 (en) 2013-05-27 2015-03-10 Novartis Ag Pyrazolopyrrolidine derivatives and their use in the treatment of disease
CN105263934B (en) 2013-05-28 2017-09-08 诺华股份有限公司 It is used as the ketone derivatives of pyrazoles pyrrolizine 4 and its purposes in treatment disease of BET inhibitor
KR20160012197A (en) 2013-05-28 2016-02-02 노파르티스 아게 Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease
JO3425B1 (en) 2013-07-15 2019-10-20 Novartis Ag Piperidinyl indole derivatives and their use as complement factor b inhibitors
SG11201600241RA (en) 2013-07-18 2016-02-26 Novartis Ag Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core
US20160168119A1 (en) 2013-07-18 2016-06-16 Novartis Ag Autotaxin inhibitors
KR102318727B1 (en) 2013-07-31 2021-10-28 노파르티스 아게 1,4-disubstituted pyridazine derivatives and their use for treating smn-deficiency-related conditions
MX367723B (en) 2013-10-25 2019-09-03 Novartis Ag Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors.
JP2016535042A (en) 2013-10-30 2016-11-10 ノバルティス アーゲー 2-Benzyl-benzimidazole complement factor B inhibitor and uses thereof
EP3063143B1 (en) 2013-11-01 2018-05-16 Novartis AG Aminoheteroaryl benzamides as kinase inhibitors
WO2015066413A1 (en) 2013-11-01 2015-05-07 Novartis Ag Oxazolidinone hydroxamic acid compounds for the treatment of bacterial infections
EP3068762B1 (en) * 2013-11-11 2019-12-25 Collaborative Medicinal Development, LLC Metal complexes and methods of treatment
CN105916857B (en) 2013-11-21 2018-06-22 诺华股份有限公司 Pyrrolopyrrolone derivatives and its purposes as BET inhibitor
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
PT3082877T (en) 2013-12-17 2019-12-03 Novartis Ag Cytotoxic peptides and conjugates thereof
AU2014364565B2 (en) 2013-12-19 2017-06-15 Novartis Ag [1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis
JP6500024B2 (en) 2013-12-20 2019-04-10 ノバルティス アーゲー Heteroaryl butanoic acid derivatives as LTA4H inhibitors
WO2015102929A1 (en) 2013-12-30 2015-07-09 Novartis Ag Tricyclic sulfonamide derivatives
BR112016020333B1 (en) 2014-03-24 2022-08-09 Novartis Ag ORGANIC COMPOUNDS OF MONOBACTAM, THEIR USES, COMPOSITIONS AND PHARMACEUTICAL COMBINATIONS
TW201602089A (en) 2014-04-17 2016-01-16 諾華公司 Polycyclic HERG activators
EP3134401B1 (en) 2014-04-22 2018-06-13 Novartis AG Isoxazoline hydroxamic acid derivatives as lpxc inhibitors
AU2014391605A1 (en) 2014-04-24 2016-10-27 Novartis Ag Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
MX2016013812A (en) 2014-04-24 2017-03-09 Novartis Ag Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors.
CN106458966B (en) 2014-04-24 2019-05-07 诺华股份有限公司 Pyrazines derivatives as inhibitors of phosphatidylinositol3 3-kinase
US20170037030A1 (en) 2014-04-24 2017-02-09 Novartis Ag Autotaxin inhibitors
MA39972A (en) 2014-05-13 2015-11-19 Choi Ha Soon Compounds and compositions for inducing chondrogenesis
WO2015173656A1 (en) 2014-05-14 2015-11-19 Novartis Ag Carboxamide derivatives
TWI714528B (en) 2014-05-14 2021-01-01 瑞士商諾華公司 Carboxamide derivatives
US20170088546A1 (en) 2014-05-14 2017-03-30 Novartis Ag Carboxamide inhibitors
US9403833B2 (en) 2014-05-14 2016-08-02 Novartis Ag Carboxamide derivatives
CR20160548A (en) 2014-05-28 2017-01-02 Novartis Ag New Pirazolo Pyrimidine Derivatives and their Use as MALT1 Inhibitors
KR101905295B1 (en) 2014-06-03 2018-10-05 노파르티스 아게 Naphthyridinedione derivatives
US9884862B2 (en) 2014-06-03 2018-02-06 Novartis Ag Pyridopyrimidinedione derivatives
US9896448B2 (en) 2014-06-03 2018-02-20 Novartis Ag Pyrimido[4,5-b]quinoline-4,5(3H, 10H)-dione derivatives
KR20170016479A (en) 2014-06-13 2017-02-13 노파르티스 아게 Auristatin derivatives and conjugates thereof
TW201625584A (en) 2014-07-02 2016-07-16 諾華公司 Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators
TW201625601A (en) 2014-07-02 2016-07-16 諾華公司 Thiophen-2-yl-pyridin-2-yl-1H-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators
TW201625586A (en) 2014-07-02 2016-07-16 諾華公司 Cyclohexen-1-yl-pyridin-2-yl-1H-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators
US10160726B2 (en) 2014-08-06 2018-12-25 Novartis Ag Quinolone derivatives as antibacterials
EP3191478B1 (en) 2014-09-12 2019-05-08 Novartis AG Compounds and compositions as raf kinase inhibitors
US10392404B2 (en) 2014-09-12 2019-08-27 Novartis Ag Compounds and compositions as kinase inhibitors
UY36294A (en) 2014-09-12 2016-04-29 Novartis Ag COMPOUNDS AND COMPOSITIONS AS QUINASA INHIBITORS
WO2016049266A1 (en) * 2014-09-24 2016-03-31 Pain Therapeutics, Inc. 4:3 naltrexone: 5-methyl-2-furaldehyde cocrystal
US20180185341A1 (en) 2014-10-03 2018-07-05 Novartis Ag Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
WO2016079669A1 (en) 2014-11-19 2016-05-26 Novartis Ag Labeled amino pyrimidine derivatives
WO2016088082A1 (en) 2014-12-05 2016-06-09 Novartis Ag Amidomethyl-biaryl derivatives complement factor d inhibitors and uses thereof
RS59507B1 (en) 2014-12-16 2019-12-31 Novartis Ag Isoxazole hydroxamic acid compounds as lpxc inhibitors
ME03385B (en) 2014-12-23 2020-01-20 Novartis Ag Triazolopyrimidine compounds and uses thereof
EP3274344B1 (en) 2015-03-25 2019-04-24 Novartis Ag Formylated n-heterocyclic derivatives as fgfr4 inhibitors
ES2876974T3 (en) 2015-04-07 2021-11-15 Novartis Ag Combination therapy with chimeric antigen receptor and amino pyrimidine derivatives
EP3288948B1 (en) 2015-04-30 2019-11-20 Novartis AG Fused tricyclic pyrazole derivatives useful for modulating farnesoid x receptors
WO2016203432A1 (en) 2015-06-17 2016-12-22 Novartis Ag Antibody drug conjugates
JP6768716B2 (en) * 2015-06-19 2020-10-14 シン−ナット プロダクツ エンタープライズ エルエルシー Carboplatin-based co-crystal pharmaceutical compositions and their uses
CN107847521A (en) * 2015-06-25 2018-03-27 新纳特产品公司 Pharmaceutical co-crystals composition and application thereof
US11096936B2 (en) 2015-09-24 2021-08-24 Cassava Sciences, Inc. Cocrystals of naloxone and naltrexone
GB2543550A (en) 2015-10-21 2017-04-26 Hox Therapeutics Ltd Peptides
SG11201803480WA (en) 2015-11-13 2018-05-30 Novartis Ag Novel pyrazolo pyrimidine derivatives
CN112851578A (en) 2015-11-26 2021-05-28 诺华股份有限公司 Diaminopyridine derivatives
CN105399664A (en) * 2015-12-11 2016-03-16 吉林大学珠海学院 Deferiprone pharmaceutical cocrystal with 2,5-dihydroxybenzoic acid as precursor and preparation method thereof
CN105399665A (en) * 2015-12-11 2016-03-16 吉林大学珠海学院 Deferiprone pharmaceutical cocrystal with p-hydroxybenzoic acid as precursor and preparation method thereof
CN105541701A (en) * 2015-12-11 2016-05-04 吉林大学珠海学院 Pharmaceutical cocrystal of deferiprone with maleic acid as precursor, and preparation method thereof
HUP1500618A2 (en) 2015-12-16 2017-06-28 Druggability Tech Ip Holdco Ltd Complexes of celecoxib and its salts and derivatives, process for the preparation thereof and pharmaceutical composition containing them
EP3390404B1 (en) 2015-12-18 2021-07-21 Novartis AG Tricyclic compounds and compositions as kinase inhibitors
WO2017103888A1 (en) 2015-12-18 2017-06-22 Novartis Ag Indane derivatives and the use thereof as soluble guanylate cyclase activators
TW201728325A (en) 2016-01-21 2017-08-16 諾華公司 Compounds and compositions for the treatment of cryptosporidiosis
UY37128A (en) 2016-02-19 2017-09-29 Novartis Ag PIRIDONA TETRACYCLIC COMPOUNDS AS ANTIVIRALS
EP3423443B1 (en) 2016-03-01 2020-08-19 Novartis AG Cyano-substituted indole compounds and uses thereof as lsd1 inhibitors
ES2881776T3 (en) 2016-03-08 2021-11-30 Novartis Ag Tricyclic compounds useful for treating orthomyxovirus infections
PL3433257T3 (en) 2016-03-24 2024-02-12 Novartis Ag Alkynyl nucleoside analogs as inhibitors of human rhinovirus
WO2017175185A1 (en) 2016-04-08 2017-10-12 Novartis Ag Heteroaryl butanoic acid derivatives as lta4h inhibitors
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability
WO2017216685A1 (en) 2016-06-16 2017-12-21 Novartis Ag Pentacyclic pyridone compounds as antivirals
WO2017216686A1 (en) 2016-06-16 2017-12-21 Novartis Ag 8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
US10689378B2 (en) 2016-06-20 2020-06-23 Novartis Ag Triazolopyridine compounds and uses thereof
US11091489B2 (en) 2016-06-20 2021-08-17 Novartis Ag Crystalline forms of a triazolopyrimidine compound
CN109790166A (en) 2016-06-20 2019-05-21 诺华股份有限公司 Imidazopyridine is used for treating cancer
CN106432136B (en) * 2016-06-30 2018-12-25 中国药科大学 A kind of Hydrochioro and atenolol are total to unformed system and preparation method thereof
EA202190285A1 (en) 2016-07-20 2021-08-31 Новартис Аг AMINOPYRIDINE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS
TW201811766A (en) 2016-08-29 2018-04-01 瑞士商諾華公司 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease
JOP20170169A1 (en) 2016-08-29 2019-01-30 Novartis Ag Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections
RS62913B1 (en) 2016-09-09 2022-03-31 Novartis Ag Compounds and compositions as inhibitors of endosomal toll-like receptors
TW201811788A (en) 2016-09-09 2018-04-01 瑞士商諾華公司 Polycyclic pyridone compounds as antivirals
JOP20190053A1 (en) 2016-09-23 2019-03-21 Novartis Ag Aza-indazole compounds for use in tendon and/or ligament injuries
UY37412A (en) 2016-09-23 2018-04-30 Novartis Ag INDAZOL COMPOUNDS FOR USE IN INJURY OF TENDONS AND / OR LIGAMENTS
JOP20190061A1 (en) 2016-09-28 2019-03-26 Novartis Ag Beta-lactamase inhibitors
WO2018073753A1 (en) 2016-10-18 2018-04-26 Novartis Ag Fused tetracyclic pyridone compounds as antivirals
CN109923118A (en) 2016-11-10 2019-06-21 诺华股份有限公司 BMP synergist
US20200009135A1 (en) 2017-02-01 2020-01-09 Medivir Ab Therapeutic applications of malt1 inhibitors
KR20190133703A (en) 2017-03-24 2019-12-03 노파르티스 아게 Isoxazole Carboxamide Compounds and Uses thereof
AR111419A1 (en) 2017-04-27 2019-07-10 Novartis Ag INDAZOL PIRIDONA FUSIONED COMPOUNDS AS ANTIVIRALS
AR111658A1 (en) 2017-05-05 2019-08-07 Novartis Ag 2-TRICYCLINAL CHINOLINONES AS ANTIBACTERIAL AGENTS
UY37774A (en) 2017-06-19 2019-01-31 Novartis Ag SUBSTITUTED 5-CYANOINDOL COMPOUNDS AND USES OF THE SAME
WO2019087162A1 (en) 2017-11-06 2019-05-09 Novartis Ag Polycyclic herg activators
WO2019087163A1 (en) 2017-11-06 2019-05-09 Novartis Ag Polycyclic herg activators
CN111315749A (en) 2017-11-17 2020-06-19 诺华股份有限公司 Novel dihydroisoxazole compounds and their use in the treatment of hepatitis b
RU2020120538A (en) 2017-11-24 2021-12-24 Новартис Аг PYRIDINONE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS
CN111433210A (en) 2017-12-20 2020-07-17 诺华股份有限公司 Fused tricyclic pyrazolo-dihydropyrazinyl-pyridinone compounds as antiviral agents
JP7291632B2 (en) 2017-12-21 2023-06-15 杏林製薬株式会社 nocturia treatment
UY38072A (en) 2018-02-07 2019-10-01 Novartis Ag COMPOSITIONS DERIVED FROM BUTANOIC ESTER SUBSTITUTED WITH BISPHENYL AS INHIBITORS OF NEP, COMPOSITIONS AND COMBINATIONS OF THE SAME
CN112041294B (en) * 2018-02-23 2024-02-20 晶体工程智能研究中心 Co-crystals of panthenol and compositions comprising said co-crystals
NZ767072A (en) 2018-02-28 2024-03-22 Novartis Ag 10-(di(phenyl)methyl)-4-hydroxy-8,9,9a,10-tetrahydro-7h-pyrrolo[1 ‘,2’:4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza
US20200407365A1 (en) 2018-02-28 2020-12-31 Novartis Ag Indole-2-carbonyl compounds and their use for the treatment of hepatitis b
JP7440101B2 (en) 2018-05-22 2024-02-28 ジェイエス・イノメッド・ホールディングス・リミテッド Heterocyclic compounds as kinase inhibitors, compositions containing heterocyclic compounds, and methods of using them
EP3810598A1 (en) 2018-06-19 2021-04-28 Novartis AG Cyanotriazole compounds and uses thereof
GB201811825D0 (en) 2018-07-19 2018-09-05 Benevolentai Bio Ltd Organic compounds
MX2021000977A (en) 2018-07-26 2021-04-12 Sumitomo Pharma Oncology Inc Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same.
FI3837256T3 (en) 2018-08-17 2023-05-15 Novartis Ag Urea compounds and compositions as smarca2/brm-atpase inhibitors
GB201813791D0 (en) 2018-08-23 2018-10-10 Benevolental Bio Ltd Organic compounds
WO2020053654A1 (en) 2018-09-12 2020-03-19 Novartis Ag Antiviral pyridopyrazinedione compounds
WO2020058913A1 (en) 2018-09-21 2020-03-26 Novartis Ag Isoxazole carboxamide compounds and uses thereof
TW202028208A (en) 2018-10-09 2020-08-01 瑞士商諾華公司 N-(4-fluoro-3-(6-(3-methylpyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl)-2,4-dimethyloxazole-5-carboxamide solid forms
JP2022514253A (en) 2018-12-18 2022-02-10 ノバルティス アーゲー N- (Pyridine-2-ylsulfonyl) cyclopropanecarboxamide derivative and its use in the treatment of CFTR-mediated diseases
MX2021008303A (en) 2019-01-11 2021-10-13 Novartis Ag Lta4h inhibitors for the treatment of hidradenitis suppurativa.
MA54755A (en) 2019-01-18 2021-11-24 Biogen Ma Inc IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS
WO2020154581A1 (en) * 2019-01-24 2020-07-30 Assia Chemical Industries Ltd Solid state forms of fedovapagon-salicyclic acid co-crystal
JP2022519923A (en) 2019-03-22 2022-03-25 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド Compositions comprising a PKM2 modulator and methods of treatment using it
KR20220019015A (en) 2019-06-10 2022-02-15 노파르티스 아게 Pyridine and pyrazine derivatives for the treatment of CF, COPD, and bronchiectasis
MX2021015499A (en) 2019-06-27 2022-04-20 Biogen Ma Inc 2h-indazole derivatives and their use in the treatment of disease.
MA56390A (en) 2019-06-27 2022-05-04 Biogen Ma Inc IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF A DISEASE
MX2022000164A (en) 2019-07-03 2022-04-01 Sumitomo Pharma Oncology Inc Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof.
WO2021038426A1 (en) 2019-08-28 2021-03-04 Novartis Ag Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
WO2021044351A1 (en) 2019-09-06 2021-03-11 Novartis Ag Methods of treating liver disease using lta4h inhibitors
JP2021054781A (en) * 2019-09-26 2021-04-08 デボン エルエス，リミテッド Co-crystalline efinaconazole and method for producing the same
AR120045A1 (en) 2019-09-26 2022-01-26 Novartis Ag PYRAZOLOPYRIDINONE ANTIVIRAL COMPOUNDS
IL293530A (en) 2019-12-18 2022-08-01 Novartis Ag 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
JP2023511170A (en) 2020-01-22 2023-03-16 ベネボレントエーアイ バイオ リミティド Pharmaceutical composition and its use
CN115315254A (en) 2020-01-22 2022-11-08 博善人工智能生物科技有限公司 Pharmaceutical composition and use thereof
EP3884938A1 (en) 2020-03-25 2021-09-29 ArtemiFlow GmbH 1,2,4-trioxane compounds and compositions comprising the same for use in the treatment of covid-19
CN115916763A (en) 2020-04-20 2023-04-04 诺华股份有限公司 Antivirals 1, 3-dioxoindene compounds
WO2021214080A1 (en) 2020-04-20 2021-10-28 Novartis Ag Antiviral 1,3-di-oxo-indene compounds
CN113582927B (en) * 2020-04-30 2023-07-04 苏州恩华生物医药科技有限公司 Celecoxib and pregabalin co-amorphous substance and preparation method thereof
IL298109A (en) 2020-05-13 2023-01-01 Chdi Foundation Inc Htt modulators for treating huntington's disease
WO2021253180A1 (en) 2020-06-15 2021-12-23 Novartis Ag Methyl (r) -2- (fluoromethyl) -5-oxo-4-phenyl-4, 5, 6, 7-tetrahydro-1h-cyclopenta [b] pyridine-3-carboxylate and methyl (r) -2- (fluoromethyl) -5-oxo-4-phenyl-1, 4, 5, 7-tetrahydrofuro [3, 4-b] pyridine-3-carboxylate as cav1.2 activators
AR122613A1 (en) 2020-06-16 2022-09-21 Novartis Ag METHYL 2-METHYL-5-OXO-1,4,5,7-TETRAHYDROFURO[3,4-B]PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CAV1.2 ACTIVATORS
PE20231099A1 (en) 2020-09-17 2023-07-18 Novartis Ag COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF Sppl2a
CN112552189A (en) * 2020-11-10 2021-03-26 中国海洋大学 Pharmaceutical co-crystal of amantadine hydrochloride and resveratrol and preparation method thereof
CN112521292B (en) * 2020-12-18 2022-02-11 深圳市萱嘉生物科技有限公司 Eutectic crystal of betaine and organic acid and preparation method and application thereof
UY39584A (en) 2020-12-22 2022-07-29 Biogen Ma Inc IMIDAZO[1,2-a]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES
WO2022140415A1 (en) 2020-12-22 2022-06-30 Biogen Ma Inc. 2h-indazole derivatives as irak4 inhibitors and their use in the treatment of disease
EP4274832A1 (en) 2021-01-07 2023-11-15 Biogen MA Inc. Tyk2 inhibitors
UY39671A (en) 2021-03-15 2022-10-31 Novartis Ag Pyrazolopyridine derivatives and their uses.
EP4308559A1 (en) 2021-03-15 2024-01-24 Novartis AG Benzisoxazole derivatives and uses thereof
UY39681A (en) 2021-03-26 2022-10-31 Novartis Ag 1,3-Substituted Cyclobutyl Derivatives and Their Uses
WO2022217232A1 (en) 2021-04-10 2022-10-13 Sunovion Pharmaceuticals Inc. Chromans and benzofurans as 5-ht1a and taar1 agonists
WO2022217248A1 (en) 2021-04-10 2022-10-13 Sunovion Pharmaceuticals Inc. Substituted sulfonamide-chroman compounds, and pharmaceutical compositions, and methods of use thereof
US11932630B2 (en) 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives
WO2022234287A1 (en) 2021-05-06 2022-11-10 Benevolentai Bio Limited Imidazopyridazine derivatives useful as trk inhibitors
CA3219799A1 (en) 2021-05-26 2022-12-01 Novartis Ag Triazolo-pyrimidine analogues for treating diseases connected to the inhibiton of werner syndrome recq helicase (wrn)
AU2022284366A1 (en) 2021-06-03 2023-10-26 Novartis Ag 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and medical uses thereof
WO2023275796A1 (en) 2021-07-01 2023-01-05 Novartis Ag Heterocyclic derivatives as sphingosine-1-phosphate 3 inhibitors
AU2022313600A1 (en) 2021-07-22 2024-02-08 Novartis Ag Substituted pyridone compounds useful to treat orthomyxovirus infections
US20230241024A1 (en) 2021-09-23 2023-08-03 Sunovion Pharmaceuticals Inc. Methods of treating metabolic disorders
CN113845438B (en) * 2021-10-12 2023-02-21 河北大学 Acetaminophen-piracetam pharmaceutical co-crystal and preparation method thereof
AR127698A1 (en) 2021-11-23 2024-02-21 Novartis Ag NAFTYRIDINOONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER
CN114031515B (en) * 2021-11-29 2022-10-21 河北大学 Acetaminophen-ibuprofen pharmaceutical co-crystal and preparation method thereof
WO2023111799A1 (en) 2021-12-13 2023-06-22 Novartis Ag PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CaV1.2 ACTIVATORS
WO2023139534A1 (en) 2022-01-24 2023-07-27 Novartis Ag Spirocyclic piperidinyl derivatives as complement factor b inhibitors and uses thereof
CN114644669A (en) * 2022-03-10 2022-06-21 华润紫竹药业有限公司 Preparation method and application of progesterone eutectic
WO2023187715A1 (en) 2022-04-01 2023-10-05 Novartis Ag Complement factor b inhibitors and uses thereof
CN114835657A (en) * 2022-06-10 2022-08-02 大连工业大学 Method for regulating and controlling ethenzamide-saccharin eutectic crystal polycrystalline type based on ionic liquid
WO2024006493A1 (en) 2022-07-01 2024-01-04 Biogen Ma Inc. Tyk2 inhibitors
US20240067627A1 (en) 2022-08-03 2024-02-29 Novartis Ag Nlrp3 inflammasome inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001042221A1 (en) * 1999-12-08 2001-06-14 Pharmacia Corporation Solid-state form of celecoxib having enhanced bioavailability
WO2001042222A1 (en) * 1999-12-08 2001-06-14 Pharmacia Corporation Polymorphic crystalline forms of celecoxib
WO2001051919A2 (en) * 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
WO2003033462A2 (en) * 2001-10-15 2003-04-24 The Regents Of The University Of Michigan Systems and methods for the generation of crystalline polymorphs
WO2003074474A2 (en) * 2002-03-01 2003-09-12 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8500862D0 (en) * 1985-01-14 1985-02-20 Tate & Lyle Plc Composition
ATE550022T1 (en) * 2003-02-28 2012-04-15 Mcneil Ppc Inc PHARMACEUTICAL MIXED CRYSTALS OF CELECOXIB-NICOTINAMIDE

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001042221A1 (en) * 1999-12-08 2001-06-14 Pharmacia Corporation Solid-state form of celecoxib having enhanced bioavailability
WO2001042222A1 (en) * 1999-12-08 2001-06-14 Pharmacia Corporation Polymorphic crystalline forms of celecoxib
WO2001051919A2 (en) * 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
WO2003033462A2 (en) * 2001-10-15 2003-04-24 The Regents Of The University Of Michigan Systems and methods for the generation of crystalline polymorphs
WO2003074474A2 (en) * 2002-03-01 2003-09-12 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WEISSBUCH I ET AL: "Understanding and control of nucleation, growth, habit, dissolution and structure of two- and three-dimensional crystals using 'tailor-made' auxiliaries", 1995, ACTA CRYSTALLOGRAPHICA. SECTION B, STRUCTURAL SCIENCE, MUNKSGAARD, COPENHAGEN, DK, PAGE(S) 115-148, ISSN: 0108-7681, XP002960386 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8555875B2 (en) 2008-12-23 2013-10-15 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
US9161912B2 (en) 2008-12-23 2015-10-20 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds

Also Published As

Publication number Publication date
EP1631260A2 (en) 2006-03-08
WO2004078163A2 (en) 2004-09-16
JP2007524596A (en) 2007-08-30
CA2514733A1 (en) 2004-09-16

Similar Documents

Publication Publication Date Title
WO2004078163A3 (en) Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
AU2003272270A1 (en) Pharmaceutical co-crystal compositions of drugs such as carbamazeptine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
Khodade et al. Development of S-substituted thioisothioureas as efficient hydropersulfide precursors
RU2016150386A (en) HETEROCYCLIC MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS
BRPI0613371B8 (en) cartridge for the storage and release of a two-phase compound
BR9914858A (en) Prostaglandin endoperoxide biosynthesis inhibitors h
ATE515260T1 (en) STABLE NANOCAPSULE SYSTEMS FOR THE ADMINISTRATION OF ACTIVE INGREDIENTS
AR052523A1 (en) PHARMACEUTICAL COMPOSITIONS OF AN NON-STEROID ANTI-INFLAMMATORY PHARMACO
BR0307599A (en) Sulphonylamino derivatives as histone deacetylase inhibitors
WO2009043049A3 (en) Pharmaceutical formulations
CA2297832A1 (en) Pellet-type formulation intended for treating the intestinal tract
BR0200982A (en) Alpha-amino sulfonyl acid compounds, a process for their preparation and pharmaceutical compositions comprising the same
MXPA06011467A (en) Active substance combination comprising a carbinol combined to at least an nsaid.
CL2003002611A1 (en) COMPOUNDS DERIVED FROM THE HYDROXAMIC THIOPHEN ACID, 2-HYDROXAMIDE-5 - [(ARIL OR HETEROARIL) -DISUTITUTED-METHYL] -AMIDE OF THE THYMPHENE-2,5-DICARBOXYL DYNAMIC ACID, PHARMACEUTICAL COMPOSITION FOR PREPARATION AND USE D
BRPI0907414A2 (en) oral dosage form containing at least two medicinal products
DK1943232T3 (en) Quadric acid derivatives as inhibitors of histone deacetylase
DE502004009582D1 (en) Mehrkomponenten-thin-to-thick-system
Zheng-Nan et al. Prodrugs of hydrogen sulfide and related sulfur species: recent development
WO2006097460A8 (en) Hydroxamates as histone deacetylase inhibitors and pharmaceutical formulations containing them
ID26972A (en) TIOESTER ACID S-SUBSTITUTION 11β-BENZALDOXINS ESTRA-4,9-DIENACARBONATE, PROCESS FOR MAKING AND PHARMACEUTICAL PROPERTIES CONTAINED FROM THIS COMPOUND
CN101128200A (en) Composition for inhibition of cathepsin K
Geurs et al. The zinc-binding group effect: lessons from non-hydroxamic acid vorinostat analogs
WO2005046727A3 (en) Ibuprofen-containing soft gelatin capsules
WO2004113391A3 (en) Improved pharmaceutical drug candidates and methods for preparation thereof
TW200507838A (en) Active substance combination comprising a 2,5-dihydroxybenzenesulfonic compound and a potassium ion channel modulator

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2514733

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007059356

Country of ref document: US

Ref document number: 10546963

Country of ref document: US

Ref document number: 2006508979

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004715190

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004715190

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10546963

Country of ref document: US